JERSEY CITY, N.J., June 28, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced three presentations on investigational ND0612 in Parkinson's disease (PD) will be shared at the 10th Congress of the European Academy of Neurology (EAN), being held in Helsinki, Finland, June 29 – July 2.
SAINT-CLOUD, France, June 17, 2024 /PRNewswire/ -- Ethypharm has entered into an agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) to acquire the selective antithrombin agent, Argatroban monohydrate (Argatra®, Arganova®, Novastan®, Exembol®), in Europe
JERSEY CITY, N.J., June 17, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced results from two studies of RADICAVA® (edaravone) for amyotrophic lateral sclerosis (ALS) at the European Network to Cure Amyotrophic Lateral Sclerosis (ENCALS) 2024 meeting. Findings from an ongoing real-world study utilizing information in the ALS/MND Natural History Study Consortium (Consortium) database of people living with ALS initiating treatment with RADICAVA suggest an additional survival benefit of 3.2 months with RADICAVA ± riluzole compared to treatment with riluzole alone. Separately, positive results from Study MT-1186-A03 (NCT04577404), a Phase 3 study evaluating the long-term safety of RADICAVA ORS® (edaravone), showed no new safety concerns and that RADICAVA ORS was well-tolerated during the 96-week study period.
JERSEY CITY, N.J., June 5, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced eight presentations at the European Network to Cure Amyotrophic Lateral Sclerosis (ENCALS) 2024 Annual Meeting being held in Stockholm, Sweden from June 17-20, 2024. The presentations will cover a wide range of translational research in amyotrophic lateral sclerosis (ALS), including the extension study results from the pivotal Phase 3 trial (MT-1186-A01) that contributed to RADICAVA® (edaravone) U.S. approval.
JERSEY CITY, N.J., May 23, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) is aware of recent external challenges facing the amyotrophic lateral sclerosis (ALS) treatment landscape. We know firsthand the great need for ALS treatments and when there is a setback for one of us, the entire community is affected.
JERSEY CITY, N.J., May 16, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced two presentations on investigational ND0612 in Parkinson's disease (PD) will be shared at the International Association of Parkinsonism and Related Disorders (IAPRD) XXIX World Congress on Parkinson's Disease and Related Disorders, being held in Lisbon, Portugal, May 19-22.
TOKYO, May 8, 2024 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.64 billion (USD 10.8 million1) in four projects for the development of new drugs for malaria and neglected tropical diseases (NTDs).2
JERSEY CITY, N.J., May 3, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of an abstract in amyotrophic lateral sclerosis (ALS) at the Professional Society for Health Economics and Outcomes Research (ISPOR) 2024 Annual Meeting, being held in Atlanta, Ga., May 5-8, 2024. The presentation will include updated results from an ongoing analysis of real-world data from RADICAVA ORS® (edaravone)-treated people living with ALS.
JERSEY CITY, N.J., April 29, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) is celebrating its eight-year anniversary of being established in the United States (U.S.). In 2016, MTPA was created as a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), with the goal of developing and advancing the company's pipeline in the U.S. while focusing on improving research in the areas of amyotrophic lateral sclerosis (ALS), erythropoietic protoporphyria (EPP), Parkinson's disease, spinal cord injury and systemic sclerosis.
JERSEY CITY, N.J., April 15, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of one abstract in amyotrophic lateral sclerosis (ALS) at the Academy of Managed Care Pharmacy (AMCP) 2024 Annual Meeting, being held in New Orleans, La., Apr. 15-18, 2024.